Lifevantage Corp (LFVN) stock
LFVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 16/3023% below fair value
$4.97−0.07 (-1.39%)
Close on Nov 13, 2026Market cap $62.26MP/E 23.7Yield 3.72%
Lifevantage EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Lifevantage's EPS for the twelve months ending Sep 30, 2026 was $0.21, down 72.7% year over year. For fiscal 2026 it was $0.40, down 46.7% from the year before. Over ten years it grew -0.5% a year on average. The highest annual figure on record is $0.90 in fiscal 2021.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $0.40 | -46.7% |
| FY2025 | Jun 30, 2025 | $0.75 | +226.1% |
| FY2024 | Jun 30, 2024 | $0.23 | +15.0% |
| FY2023 | Jun 30, 2023 | $0.20 | -16.7% |
| FY2022 | Jun 30, 2022 | $0.24 | -73.3% |
| FY2021 | Jun 30, 2021 | $0.90 | +13.9% |
| FY2020 | Jun 30, 2020 | $0.79 | +58.0% |
| FY2019 | Jun 30, 2019 | $0.50 | +22.0% |
| FY2018 | Jun 30, 2018 | $0.41 | +272.7% |
| FY2017 | Jun 30, 2017 | $0.11 | -73.8% |
| FY2016 | Jun 30, 2016 | $0.42 | -16.0% |
| FY2015 | Jun 30, 2015 | $0.50 | -29.6% |
| FY2014 | Jun 30, 2014 | $0.71 | +69.0% |
| FY2013 | Jun 30, 2013 | $0.42 | -45.5% |
| FY2012 | Jun 30, 2012 | $0.77 | – |
| FY2011 | Jun 30, 2011 | -$4.83 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | -$0.02 | -111.8% |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $0.10 | -33.3% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $0.11 | -57.7% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $0.02 | -89.5% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $0.17 | +21.4% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $0.15 | +50.0% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $0.26 | +100.0% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $0.19 | – |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $0.14 | +180.0% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $0.10 | -37.5% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $0.13 | +62.5% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$0.05 | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $0.05 | 0.0% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $0.16 | – |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $0.08 | -11.1% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$0.08 | -900.0% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $0.05 | -80.0% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$0.11 | -131.4% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $0.09 | -25.0% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $0.01 | -96.2% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $0.25 | +47.1% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $0.35 | +34.6% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $0.12 | +9.1% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $0.26 | -13.3% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $0.17 | +41.7% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $0.26 | 0.0% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $0.11 | -8.3% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $0.30 | +400.0% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $0.12 | +100.0% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $0.26 | +23.8% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $0.12 | 0.0% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $0.06 | +200.0% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $0.06 | 0.0% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $0.21 | +2000.0% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $0.12 | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $0.02 | 0.0% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $0.06 | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $0.01 | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $0.00 | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $0.02 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?